Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000792

Drug Information
NameRaloxifene
SynonymsRaloxifeno [Spanish]; LY 139481; Methanone, [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-; Raloxifene Hcl; KBioSS_002364; LY-139481; BSPBio_000903; 84449-90-1; [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl]{4-[(2-piperidin-1-ylethyl)oxy]phenyl}methanone; Keoxifene; KBio2_002361; RAL; CCRIS 7129; SPBio_002824; SMP2_000095; Raloxifene [INN:BAN]; HMS2089F06; CHEBI:8772; Raloxifenum; NSC747974; NCGC00015889-02; cMAP_000032; Eviden (TN); C28H27NO4S; DB00481; UNII-YX9162EO3I; C07228; Raloxifeno; raloxifene; BPBio1_000995; VU0155042-3; Prestwick2_000862; LS-177821; BIDD:ER0216; (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone; Lopac-R-1402; KBio3_002840; NCGC00092353-02; BIDD:GT0795; Raxeto; Raxeto (TN); MolPort-003-850-106; CHEBI:45355; CID5035; [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone; Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-; Raloxifene (INN); NCGC00015889-01; KBioGR_002361; D08465; Prestwick1_000862; HSDB 7460; [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone; 82640-04-8 (hydrochloride); CHEMBL81; [6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone; Raloxifenum [Latin]; Lopac0_001051; nchembio.76-comp4; Prestwick3_000862; NCGC00015889-07; [2-(4-Hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-(2-(1-piperidinyl)ethoxy)phenyl]methanone; KBio2_007497; CAS-82640-04-8; nchembio.140-comp6; KBio2_004929; (2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone; AC1L1JGT; Eviden; Prestwick0_000862
Trade NameEvista
CompanyEli Lilly and Company
IndicationOsteoporosis in post-menopausal women
[ICD9: 733.0   ICD10: M80-M81]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)
34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,1
8,30-31H,1-3,14-17H2
InChIKeyGZUITABIAKMVPG-UHFFFAOYSA-N
Canonical SMILESC1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O    
Therapeutic ClassBone Density Conservation Agents
CAS NumberCAS 84449-90-1
FormulaC28H27NO4S
PubChem Compound IDCID 5035.
PubChem Substance IDSID 9437.
ChEBI8772;
SuperDrug ATC IDG03XC01
SuperDrug CAS ID084449901;
TargetEstrogen receptorModulator[2]
Ref 1New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. To Reference
Ref 2Raloxifene: risks and benefits. Ann N Y Acad Sci. 2001 Dec;949:295-303. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543